Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management

Area of Science:

• Oncology
• Dermatology
• Pathology

Background:

• Mogamulizumab, a CCR4-directed monoclonal antibody, shows significant efficacy in relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS).
• Rash is a frequent adverse event associated with mogamulizumab treatment in MF/SS patients.
• The complex presentation of MF/SS and mogamulizumab-induced rash can challenge accurate diagnosis and management.

Purpose of the Study:

• To develop clinical best practice recommendations for identifying and managing mogamulizumab-associated rash.
• To synthesize existing literature with expert clinical experience and institutional insights.
• To aid healthcare providers in distinguishing rash from disease progression and implementing appropriate treatment strategies.

Main Methods:

• Literature review of published studies on mogamulizumab in MF/SS.
• Consolidation of clinical experiences and recommendations from multiple investigators and institutions.
• Development of a multidisciplinary approach involving oncology, dermatology, and pathology.

Main Results:

• Mogamulizumab demonstrates improved progression-free survival and overall response rates compared to vorinostat.
• Rash is a common, yet generally manageable, adverse event requiring careful clinical evaluation.
• Optimal management strategies involve biopsy confirmation and corticosteroid therapy.

Conclusions:

• Effective management of mogamulizumab-associated rash necessitates a collaborative effort between oncology, dermatology, and pathology.
• Early identification and appropriate treatment of rash are crucial for patient care and treatment adherence.
• Clinical best practice guidelines can enhance the management of this common adverse event in MF/SS patients treated with mogamulizumab.